版本:
中国

BRIEF-Galena Biopharma says combination of trastuzumab and NeuVax in HER2 low-expressing patients is well-tolerated

Oct 10 Galena Biopharma Inc :

* Galena Biopharma Inc - combination of trastuzumab and neuvax in HER2 low-expressing (le) patients is well-tolerated

* Galena Biopharma Inc - cardiac effects of trastuzumab are not impacted by addition of NeuVax

* Galena Biopharma Inc - there was one CG patient who experienced a grade 3 cardiac adverse event during trial

* Galena Biopharma- after 12 months of follow-up combination of trastuzumab and neuvax , co expects to report first interim efficacy,immunologic outcomes at end of 2017 Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐